SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13D (Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)

RULE 15U-2(a)
(Amendment No. 3)
LABORATORY CORPORATION OF AMERICA HOLDINGS
(Name of Issuer)
COMMON STOCK, \$0.10 PAR VALUE
(Title of Class of Securities)
50540R 10 2
(CUSIP Number)
Peter R. Douglas Davis Polk & Wardwell 450 Lexington Avenue New York, NY 10017 Tel. No.: (212) 450-4000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
October 18, 2000
(Date of Event which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1 (b)(3) or (4), check the following box $ _ $.
Note. This document is being electronically filed with the Commission using the EDGAR system. See Rule 13d-1 (a) for other parties to whom copies are to be sent.
*The remainder of this cover page should be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Schedule 13D
CUSIP No. 50540R 10 2 13D Page 2 of 4 Pages
1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Roche Holdings, Inc. 51-0304944

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) [] (b) []

3	SEC USE ONLY			
4	SOURCE OF FUND)S		
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e).			
6	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7 SOLE VOTING POWER	11,352,537 shares of Common Stock	
			N/A	
		9 SOLE DISPOSITIVE POWER	11,352,537 shares of Common Stock	
		10 SHARED DISPOSITIVE POWER	N/A	
11	11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11,352,537 shares of Common Stock			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES []			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 32.71% of Common Stock			
14	TYPE OF REPORTING PERSON CO, HC			

The following information amends and supplements the Schedule 13D dated April 28, 1995, as previously amended (as so amended, the "Schedule 13D").

Item 1. Security and Issuer.

Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows:

This statement relates to the Common Stock, par value \$0.10 per share (the "Common Stock") of Laboratory Corporation of America Holdings, a Delaware corporation (the "Company"). The principal executive offices of the Company are located at 358 South Main Street, Burlington, North Carolina 27215.

Item 4. Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended by adding the following:

On October 18, 2000 Holdings sold 4 million shares of Common Stock in a registered public offering resulting in proceeds to Holdings of \$115.10 per share. Prior to the offering Holdings owned 15,352,537 shares or 44.53% of the Company's Common Stock. Immediately following the offering, Holdings' ownership of the Company's Common Stock was approximately 32.71%.

The Company has filed a registration statement with the Securities and Exchange Commission relating to the proposed offer and sale by Holdings of the Company's Common Stock.

Dated: October 25, 2000

ROCHE HOLDINGS, INC.

By: /s/ Marcel Kohler

Name: Marcel Kohler Title: Secretary